Molecular Characterization of Head and Neck Cancer

摘要: Molecular targeted therapy in head and neck squamous cell carcinoma (HNSCC) continues to make strides, holds much promise. Cetuximab remains the sole US FDA-approved molecular available for HNSCC, though several new biologic agents targeting epidermal growth factor receptor (EGFR) other pathways are currently regulatory approval pipeline. While therapies have potential be personalized, their current use HNSCC is not personalized. This illustrated EGFR-targeted drugs, where EGFR as a target has yet individualized HNSCC. Future research needs identify factors that correlate with response (or lack of one) underlying genotype-phenotype relationship dictates this response. Comprehensive exploration genetic epigenetic landscapes opening frontiers further enlighten mechanistically inform newer well existing targets, set course eventually translating these discoveries into patients. opinion offers snapshot evolution subtyping its clinical applicability, emergent paradigms implications controlling disease future.